Mothers against decapentaplegic homolog 2 and Mothers against decapentaplegic homolog 3 (SMAD2/3)

Mothers against decapentaplegic homolog 2 (SMAD2) and 3 (SMAD3) are critical intracellular mediators of the Transforming Growth Factor-beta (TGF-beta) signaling superfamily. As receptor-regulated SMADs (R-SMADs), they are phosphorylated by the TGF-beta type I receptor (ALK5) upon ligand binding, subsequently forming a heteromeric complex with SMAD4 to translocate into the nucleus and regulate the transcription of target genes. These proteins play fundamental roles in regulating cell growth, differentiation, apoptosis, and the production of extracellular matrix components. In pathological states, SMAD2/3 signaling is a primary driver of tissue fibrosis in the liver, lungs, and kidneys, and it plays a dual role in oncology, acting as a tumor suppressor in early-stage disease but promoting metastasis and immune evasion in advanced cancers. Therapeutic targeting of the SMAD2/3 pathway, often through the inhibition of upstream receptors or direct modulation of SMAD activity, is a major area of drug development for treating fibrotic diseases and refractory solid tumors.

Other names

SMAD2/3MADH2/3JV18-1hMAD-2hMAD-3Receptor-regulated SMADR-SMAD

Inhibition of phosphorylation by TGF-beta type I receptors, disruption of SMAD2/3-SMAD4 complex formation, and blockade of nuclear translocation or DNA binding to prevent the transcription of pro-fibrotic and pro-oncogenic genes.